Skip Navigation LinksHome > October 2012 - Volume 34 - Issue 7 > Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refr...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e31826b9d25
Clinical and Laboratory Observations

Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric Sarcomas

Hingorani, Pooja MD; Eshun, Francis MD; White-Collins, Andrea PNP; Watanabe, Masayo MD

Collapse Box


Background: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients.

Observations: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months.

Conclusions: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.